VE303 for Prevention of Recurrent Clostridioides Difficile Infection
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE...
LMN-201 for Prevention of C. Difficile Infection Recurrence
This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy...
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10 days with standard ther...
Top Cities for Clostridioides Difficile Infection Clinical Trials
Clostridioides Difficile Infection clinical trials are recruiting across 21 cities. Here are the cities with the most active studies:
About Clostridioides Difficile Infection
Clostridioides difficile infection is a bacterial infection that causes inflammation of the colon, often following antibiotic use. It can cause severe diarrhea and life-threatening colitis. Treatment includes specific antibiotics, and fecal microbiota transplantation for recurrent cases.
Clinical trials are advancing new treatments for clostridioides difficile infection. Currently, 3 studies are recruiting a combined 1,487 participants across the United States. Research is being conducted by 3 organizations including Vedanta Biosciences, Inc., Lumen Bioscience, Inc., University of Virginia.
2026 Clostridioides Difficile Infection Research Landscape
As of March 2026, the clostridioides difficile infection clinical trial landscape includes 3 actively recruiting studies across 21 cities in the United States. These studies are collectively seeking 1,487 participants, with an average enrollment target of 496 per study.
Research is being led by 3 different organizations, including Vedanta Biosciences, Inc., Lumen Bioscience, Inc., University of Virginia.
Geographically, clostridioides difficile infection trials are most concentrated in Hamden, Connecticut (2 trials); Chandler, Arizona (1 trial); Apple Valley, California (1 trial); Culver City, California (1 trial); San Diego, California (1 trial) and 7 other cities.
Featured Clostridioides Difficile Infection Studies
Highlighted recruiting studies for clostridioides difficile infection, selected by enrollment size and research scope.
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).
LMN-201 for Prevention of C. Difficile Infection Recurrence
This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10 days with standard therapy among first time incident cases of uncomplicated C. difficile infection (CDI) in hospitalized, or outpatient, persons aged 18 or older. The investigators hypothesis is that alanyl-glutamine supple...
Frequently Asked Questions About Clostridioides Difficile Infection Clinical Trials
Are there clostridioides difficile infection clinical trials near me?
Yes, there are 3 clostridioides difficile infection clinical trials currently recruiting across 21+ cities in the United States, including Hamden, Connecticut; Chandler, Arizona; Apple Valley, California. Browse the studies above to find one at a location convenient for you.
How do I join a clostridioides difficile infection clinical trial?
To join a clostridioides difficile infection clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are clostridioides difficile infection clinical trials free?
Yes, participation in clostridioides difficile infection clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of clostridioides difficile infection treatments are being studied?
Current clostridioides difficile infection clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 3 research organizations.
Is it safe to participate in clostridioides difficile infection clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov